Treatment of Verruca Vulgaris With Topical Cidofovir

JAMA: The Journal of the American Medical Association

Volumn 278, Issue 15, 1997, Pages 1236-

  Zabawski, Edward J ^a   Sands, Bryan ^a   Goetz, Dudley ^a   Naylor, Mark ^b   Cockerell, Clay J ^c  

^a Dallas Ft Worth Medical Center   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR;

ADULT; ANTIBIOTIC THERAPY; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; SCHOOL CHILD; TOPICAL DRUG ADMINISTRATION; VERRUCA VULGARIS;

EID: 0030796352     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1997.03550150040032     Document Type: Letter

References (5)

1. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol. 1993;3:85-96.
2. Van Cutsem E, Snoeck R, Van Ranst M, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (s)1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. J Med Virol. 1995;45:230-250.
3. Snoeck R, Van Rant M, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med. 1995;333:943.
4. Sacks S, Shafran S, Francisco D, et al. A randomized, double-blind, placebocontrolled pilot study of cidofovir topical gel for recurrent genital herpes infection. In: Poster abstracts of the American Academy of Dermatology 55th Annual Meeting; March 21-26, 1997; San Francisco, Calif. Abstract P-290.
5. Hubbert NL, Sedman SA, Schiller JT. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol. 1992;66:6237-6241.